Implant failure of the Compress prosthesis: a case report.

Background: The Compress is designed to achieve bone formation and stability by applying pressure at the bone-implant interface, minimizing the likelihood of aseptic loosening, which is a complication of stem implants. Herein, we report two cases of implant failure using the Compress.

Case Presentation: Case 1 describes a 36 year-old Japanese man who underwent extraarticular tumor resection, Compress arthroplasty, and reconstruction with a gastrocnemius flap after preoperative chemotherapy for a secondary malignant giant cell tumor in the right distal femur.

Selumetinib for symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1: the first single-center real-world case series in Japan.

Objective: In Japan, selumetinib is used in pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic inoperable plexiform neurofibroma (PN). However, there have been no real-world reports on Japanese patients. In this study, we reported a single-center, short-term experience with selumetinib after its approval in Japan.

A combination cyanobacterial treatment approach using hydrogen peroxide and L-lysine successfully improved the removal efficiency of toxic cyanobacteria.

Harmful cyanobacterial blooms have been increasing globally, introducing new challenges for protecting aquatic ecosystems and human health. A combined algaecide treatment, similar to combination antibiotic therapy, may more rapidly and effectively remove cyanobacteria by broad targeting of different growth mechanisms, reducing the recovery of bloom-forming cyanobacteria. To confirm this hypothesis, hydrogen peroxide (10.

Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring mutation.

Solid tumors harboring mutations in the Braf gene () are currently treated by combination Braf/MEK inhibitor therapy, and there is an extensive literature on patient response rates. Alternatively, few studies have documented the clinical response of mutation-positive solid tumors to MEK inhibitor monotherapy. We report the case of a 57-year-old female diagnosed with papillary thyroid carcinoma and progressive lung metastases initially treated by total thyroidectomy and subsequent thyroid-stimulating hormone suppression therapy.